16 datasets found
-
Federal
Cellular cardiomyoplasty with autologous skeletal myoblasts for ischemic heart disease and heart failure
U.S. Department of Health & Human Services —
Cell transplantation to repair or regenerate injured myocardium is a new frontier in the treatment of cardiovascular disease. Even though it is based on many years of... -
Federal
Pacing in congestive heart failure
U.S. Department of Health & Human Services —
Despite the major advances in medical drug therapy, heart failure remains a syndrome associated with high mortality and morbidity. Biventricular or left ventricular... -
Federal
Cytokines as new treatment targets in chronic heart failure
U.S. Department of Health & Human Services —
Inflammatory cytokines may negatively influence contractility and contribute to the remodelling process in the failing myocardium. Traditional cardiovascular drugs... -
Federal
Infective endocarditis: too ill to be operated?
U.S. Department of Health & Human Services —
Infective endocarditis remains a disease associated with high mortality in certain groups of patients, with death resulting primarily from central nervous system... -
Federal
Debate: Do all patients with heart failure require implantable defibrillators to prevent sudden death?
U.S. Department of Health & Human Services —
Debate: Do all patients with heart failure require implantable defibrillators to prevent sudden death? -
Federal
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
U.S. Department of Health & Human Services —
Previous trials (Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure [MERIT-HF], Cardiac Insufficiency Bisoprolol Study [CIBIS] II) have... -
Federal
Beta-Adrenergic gene therapy for cardiovascular disease
U.S. Department of Health & Human Services —
Gene therapy using in vivo recombinant adenovirus-mediated gene transfer is an effective technique that offers great potential to improve existing drug treatments for... -
Federal
ELITE II and Val-HeFT are different trials: together what do they tell us?
U.S. Department of Health & Human Services —
The Losartan Heart Failure Survival Study (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT) both evaluated the efficacy and tolerability of a selective... -
Federal
Dose response of ACE inhibitors: implications of the SECURE trial
U.S. Department of Health & Human Services —
The choice of the appropriate dosage of ACE inhibitor in clinical practice is an important one. The available evidence suggests that in chronic heart failure as well... -
Federal
Biventricular pacing in heart failure: update on results from clinical trials
U.S. Department of Health & Human Services —
Biventricular pacing or resynchronisation therapy is a non-pharmacological therapy for patients with chronic heart failure. Since being originally described in 1994,... -
Federal
Debate: Should statin be used in patients with heart failure?
U.S. Department of Health & Human Services —
Statins reduce mortality of patients with coronary artery disease (CAD). However, by protocol, trials have excluded patients with chronic heart failure. Since the... -
Federal
Debate: Do all patients with heart failure require implantable defibrillators to prevent sudden death?
U.S. Department of Health & Human Services —
Sudden death is a major cause of mortality in patients with ventricular dysfunction. The highest risk occurs among patients with less severe functional impairment.... -
Federal
Debate: Statins should be used in patients with heart failure
U.S. Department of Health & Human Services —
Treatment to prevent progression of heart failure has been targeted to reverse the consequences of heart failure and to a lesser extent the cause – the... -
Federal
Debate: Do all patients with heart failure require automatic implantable defibrillators for the prevention of sudden death?
U.S. Department of Health & Human Services —
Recent clinical trials indicate that approximately two-thirds of patients in New York Heart Association (NYHA) class II and III, who comprise almost 90% of patients... -
Federal
Angiotensin receptor blockers in heart failure after the ELITE II trial
U.S. Department of Health & Human Services —
Specific blockers of the angiotensin type1 receptor, angiotensin receptor blockers (ARBs), have been introduced as an alternative to angiotensin-converting enzyme... -
Federal
Exercise training in heart failure
U.S. Department of Health & Human Services —
Chronic heart failure (CHF) is a common condition with a poor prognosis. It is associated with poor exercise tolerance and debilitating symptoms. These symptoms...
16 datasets found